Lexeo Therapeutics, Inc.

Biotechnology • Healthcare • New York, NY, United States • LXEO (NGM)

212 547 9879 345 Park Avenue South, New York, NY 10010, United States

Quarter: Q4 2025 Reported: October 17, 2025 Sentiment: Positive

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Analysis Summary

### Detailed Financial Performance Breakdown
The provided transcript, an 8-K filing, does not contain traditional quarterly financial performance metrics such as revenue, net income, earnings per share (EPS), or growth rates for Q4 2025. The company did disclose activities related to capital raising, including unregistered sales of equity securities (Private Placement) and a proposed offering, evidenced by an Underwriting Agreement and Securities Purchase Agreement dated October 16, 2025. These activities aim to bolster liquidity and capital resources, as mentioned in the forward-looking statements.

### Strategic Initiatives and Business Segment Analysis
Lexeo's primary strategic focus is advancing its gene therapy pipeline. For LX2006 (Friedreich's Ataxia), the company is pursuing an accelerated approval pathway, with the FDA open to a BLA submission that pools Phase I/II data with a planned pivotal study. A key strategic initiative involves transitioning to an optimized, high-yield Sf9-baculovirus manufacturing platform, supported by submitted Chemistry, Manufacturing and Controls (CMC) data demonstrating analytical comparability and superior purity compared to the HEK293 process. For LX2020 (PKP2-AC), the strategy involves progressing the HEROIC-PKP2 Phase I/II trial, with plans to gather and present more extensive safety and efficacy data, including cardiac biopsies, in early 2026.

### Management Commentary and Forward Guidance
While no direct management commentary is provided in this 8-K filing, the company's actions reflect a proactive engagement with the FDA to expedite LX2006's path to market and a commitment to robust data generation for LX2020. Guidance includes the expectation of providing additional LX2020 safety and clinical efficacy data in January 2026 at the J.P. Morgan Healthcare Conference. This update is expected to encompass the majority of high-dose participants with over 6 months of follow-up, three low-dose participants with over 12 months, and analyses from five cardiac biopsies from high-dose cohorts.

### Competitive Positioning and Market Trends
The transcript does not explicitly discuss competitive positioning or broader market trends for gene therapies in Friedreich's Ataxia or Arrhythmogenic Cardiomyopathy (PKP2-AC). However, the pursuit of accelerated approval and the development of an optimized manufacturing platform suggest an effort to establish a leading position in these rare disease indications.

### Risk Factors and Concerns Raised
The company highlights several risks in its cautionary note regarding forward-looking statements. These include the preliminary nature of financial estimates, global macroeconomic conditions and related volatility, the unpredictable relationship between preclinical and clinical study results, potential delays in regulatory filings or failure to receive regulatory approval, uncertainties regarding the consummation of proposed offerings, and general liquidity and capital resource risks.

### Analyst Q&A Highlights
This section is not applicable as the provided text is an 8-K filing, not an earnings call transcript that typically includes an analyst Q&A session.

Key Highlights

• FDA open to accelerated approval BLA for LX2006 by pooling Phase I/II and pivotal study data, contingent on manufacturing comparability.
• Successful analytical comparability data submitted for optimized Sf9 manufacturing platform for LX2006, showing similar frataxin expression and lower contaminating DNA.
• Interim LX2006 clinical data shows sustained or deepening improvements in cardiac and neurologic Friedreich's Ataxia measures, exceeding FDA thresholds.
• LX2020 Phase I/II trial (HEROIC-PKP2) generally well tolerated with no clinically significant complement activation and early positive cardiac parameter trends in low-dose participants.
• Upcoming comprehensive LX2020 safety and clinical efficacy data release expected in January 2026 at the J.P. Morgan Healthcare Conference.
• Company engaged in capital raising through unregistered sales of equity securities (Private Placement) and a proposed offering.

Financial Metrics

eps

N/A

YoY: N/A

revenue

N/A N/A

YoY: N/A

guidance

net income

N/A N/A

YoY: N/A

Stock Performance (90 Days)

Data through May 15, 2026

Positive Signals

• FDA's openness to an accelerated approval pathway for LX2006.
• Successful analytical comparability data for the optimized Sf9 manufacturing platform for LX2006.
• Interim LX2006 clinical data exceeding FDA-agreed efficacy thresholds for co-primary endpoints.
• LX2020's generally well-tolerated safety profile and early positive cardiac trends in low-dose cohorts.
• Strategic capital raising activities (private placement, proposed offering) to support ongoing development.

Risks & Concerns

— Unpredictable relationship between preclinical study results and clinical study results.
— Delays in submission of regulatory filings or failure to receive regulatory approval.
— Uncertainty regarding the consummation of proposed equity offerings.
— Liquidity and capital resources.
— Global macroeconomic conditions and related volatility.